Catatan efek · kuartal yang diarsipkan

LLY

Eli Lilly and Company · Healthcare · Drug Manufacturers - General

1,233.5 -1.1% kapitalisasi pasar $1.16T kuotasi tertunda (FMP) · per Aug 25 22:08 UTC — terpisah dari data pengajuan di bawah

Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024

24Pemegang yang dilacak

+2Δ pemegang

109.89MSaham yang dipegang

$97.29BNilai yang dilaporkan

+2Posisi baru

−0Keluar

Rising Skor keyakinan 46/100 Cara penghitungan ini dilakukan → Jelaskan ini di Meja Riset →

Input momentum (manajer yang sebanding): keluasan pemegang +9.1% · aliran saham -2.3% · posisi baru bersih +8.3% — formula
Fragmentasi kepemilikan — lebih banyak pemegang, agregat kepemilikan lebih kecil

Semua angka kepemilikan: hanya manajer 13F yang dipantau, posisi saham biasa, periode pelaporan Q3 2024

Kepemilikan dari waktu ke waktu

Kuartal	Pemegang	Δ	Saham	Nilai yang dilaporkan	Baru	Keluar
Q2 2026	193	+4	671.92M	$804.91B	+6	−1
Q1 2026	191	-3	666.59M	$613.20B	+1	−5
Q4 2025	193	+2	707.04M	$758.81B	+3	—
Q3 2025	27	-3	329.88M	$251.63B	+2	−6
Q2 2025	28	-1	307.45M	$239.60B	+2	−3
Q1 2025	26	0	140.32M	$115.83B	+1	−1
Q4 2024	26	+1	145.00M	$111.91B	+3	−2
Q3 2024	24	+2	109.89M	$97.29B	+2	—
Q2 2024	22	—	112.43M	$101.75B	—	—

Jumlah pemegang

Siapa yang memegangnya · Q3 2024

#	Manajer	Saham	Δ saham	Nilai	Bobotnya		Dipegang
1	T. Rowe Price ✦	20.93M	+1.4%	$18.54B	2.1%	▲ Add	2	SEC ↗
2	T. Rowe Price ✦	20.93M	+1.4%	$18.54B	2.1%	▲ Add	2	SEC ↗
3	Capital World Investors ✦	20.36M	-6.7%	$18.03B	2.8%	▼ Trim	2	SEC ↗
4	PRIMECAP Management ✦	17.69M	-9.8%	$15.67B	11.5%	▼ Trim	2	SEC ↗
5	Geode Capital Management ✦ (pasif)	17.09M	+0.5%	$15.09B	1.2%	▲ Add	2	SEC ↗
6	Geode Capital Management ✦ (pasif)	17.09M	+0.5%	$15.09B	1.2%	▲ Add	2	SEC ↗
7	Wellington Management ✦	10.61M	-1.5%	$9.40B	1.6%	▼ Trim	2	SEC ↗
8	Wellington Management ✦	10.61M	-1.5%	$9.40B	1.6%	▼ Trim	2	SEC ↗
9	Wellington Management ✦	10.61M	-1.5%	$9.40B	1.6%	▼ Trim	2	SEC ↗
10	Wellington Management ✦	10.61M	-1.5%	$9.40B	1.6%	▼ Trim	2	SEC ↗
11	Wellington Management ✦	10.61M	-1.5%	$9.40B	1.6%	▼ Trim	2	SEC ↗
12	Wellington Management ✦	10.61M	-1.5%	$9.40B	1.6%	▼ Trim	2	SEC ↗
13	Wellington Management ✦	10.61M	-1.5%	$9.40B	1.6%	▼ Trim	2	SEC ↗
14	Wellington Management ✦	10.61M	-1.5%	$9.40B	1.6%	▼ Trim	2	SEC ↗
15	Wellington Management ✦	10.61M	-1.5%	$9.40B	1.6%	▼ Trim	2	SEC ↗
16	Norges Bank ✦ (pasif)	10.49M	-4.7%	$9.29B	1.3%	▼ Trim	2	SEC ↗
17	Fisher Asset Management ✦	5.06M	+3.5%	$4.48B	1.8%	▲ Add	2	SEC ↗
18	Arrowstreet Capital ✦	1.63M	+1.3%	$1.44B	1.2%	▲ Add	2	SEC ↗
19	Millennium Management ✦	990.21K	+86.1%	$877.27M	0.8%	▲ Add	2	SEC ↗
20	Tiger Global Management ✦	969.80K	+4.3%	$859.18M	3.7%	▲ Add	2	SEC ↗
21	Marshall Wace ✦	910.13K	+15.3%	$806.32M	1.1%	▲ Add	2	SEC ↗
22	Marshall Wace ✦	910.13K	+15.3%	$806.32M	1.1%	▲ Add	2	SEC ↗
23	Marshall Wace ✦	910.13K	+15.3%	$806.32M	1.1%	▲ Add	2	SEC ↗
24	Adage Capital Partners ✦	829.38K	+0.2%	$734.78M	1.3%	▲ Add	2	SEC ↗
25	AQR Capital Management ✦	677.64K	+42.8%	$591.79M	0.8%	▲ Add	2	SEC ↗
26	AQR Capital Management ✦	677.64K	+42.8%	$591.79M	0.8%	▲ Add	2	SEC ↗
27	AQR Capital Management ✦	677.64K	+42.8%	$591.79M	0.8%	▲ Add	2	SEC ↗
28	AQR Capital Management ✦	677.64K	+42.8%	$591.79M	0.8%	▲ Add	2	SEC ↗
29	AQR Capital Management ✦	677.64K	+42.8%	$591.79M	0.8%	▲ Add	2	SEC ↗
30	D. E. Shaw & Co. ✦	408.08K	+72.0%	$361.54M	0.5%	▲ Add	2	SEC ↗
31	D. E. Shaw & Co. ✦	408.08K	+72.0%	$361.54M	0.5%	▲ Add	2	SEC ↗
32	Renaissance Technologies ✦	257.81K	Baru	$228.41M	0.3%	New	1	SEC ↗
33	Coatue Management ✦	247.95K	+19.8%	$219.67M	0.8%	▲ Add	2	SEC ↗
34	Coatue Management ✦	247.95K	+19.8%	$219.67M	0.8%	▲ Add	2	SEC ↗
35	Coatue Management ✦	247.95K	+19.8%	$219.67M	0.8%	▲ Add	2	SEC ↗
36	Coatue Management ✦	247.95K	+19.8%	$219.67M	0.8%	▲ Add	2	SEC ↗
37	Coatue Management ✦	247.95K	+19.8%	$219.67M	0.8%	▲ Add	2	SEC ↗
38	Citadel Advisors ✦	215.18K	-57.0%	$190.64M	0.2%	▼ Trim	2	SEC ↗
39	Citadel Advisors ✦	215.18K	-57.0%	$190.64M	0.2%	▼ Trim	2	SEC ↗
40	Two Sigma Investments ✦	199.74K	-11.5%	$176.95M	0.4%	▼ Trim	2	SEC ↗
41	Viking Global Investors ✦	152.04K	+5.5%	$134.70M	0.5%	▲ Add	2	SEC ↗
42	Bridgewater Associates ✦	73.27K	-23.5%	$64.91M	0.4%	▼ Trim	2	SEC ↗
43	Dodge & Cox ✦	45.09K	-1.9%	$39.95M	0.0%	▼ Trim	2	SEC ↗
44	GAMCO Investors ✦	34.81K	-2.8%	$30.84M	0.3%	▼ Trim	2	SEC ↗
45	Point72 Asset Management ✦	13.16K	Baru	$11.66M	0.0%	New	1	SEC ↗
46	Gotham Asset Management ✦	8.52K	-28.7%	$7.54M	0.1%	▼ Trim	2	SEC ↗

"Bobot mereka" = porsi posisi dari total nilai ekuitas 13F yang dilaporkan manajer tersebut — ukuran keyakinan. ✦ = manajer yang dikurasi.

Pembeli baru

Renaissance Technologies	$228.41M	0.3%
Point72 Asset Management	$11.66M	0.0%

Telah keluar

Tidak ada keluar yang terlacak kuartal ini.

Konteks pasar penuh: di SEMUA filer 13F (data terstruktur SEC, Q1 2026): 4,323 pemegang, 762.84M saham, $674.93B dilaporkan. Ini adalah periode berbeda yang lebih lama dibandingkan angka semesta yang dilacak di atas, dan keduanya tidak pernah dicampur.

Sering dimiliki bersama

Apa lagi yang paling sering dimiliki oleh pemegang efek ini yang dilacak — berdasarkan jumlah kepemilikan bersama, bukan hubungan fundamental.

GOOGL24pemegang bersama MSFT24pemegang bersama ADBE23pemegang bersama NVDA23pemegang bersama META23pemegang bersama

Transaksi orang dalam

Pembelian di pasar terbuka (P)

Tidak ada pembelian insider di pasar terbuka dalam jendela cakupan kami.

Penjualan di pasar terbuka (S)

Aug 17 Jonsson Patrik

Officer · 6.50K lbr · $7.64M

Aug 10 Zakrowski Donald A

Officer · 2.00K lbr · $2.37M

Aug 07 Hakim Anat

Officer · 5.00K lbr · $5.95M

Penghargaan, eksekusi, dan pemotongan pajak tidak pernah dihitung sebagai pembelian atau penjualan di sini. Metodologi

Kepemilikan manfaat

Jul 23 SC 13G/A — LILLY ENDOWMENT INC

Lihat pengajuan SEC asli ↗

Dalam berita

Aug 24 FDA Clears Roche And Eli Lilly's Alzheimer's Blood Test ↗

The Food and Drug Administration has cleared a new blood test from Roche and Eli Lilly designed to help identify…

Forbes

Aug 24 FDA Approves Alzheimer's Blood Test Developed by Roche and Eli Lilly ↗

The Food and Drug Administration cleared a blood test for identifying Alzheimer's disease symptoms, which was developed…

WSJ

Aug 24 Roche, Eli Lilly's Alzheimer's blood test gets FDA clearance ↗

The U.S. Food and Drug Administration has cleared Roche and partner Eli Lilly's blood test to help identify signs of…

Reuters

Aug 24 Eli Lilly Launches Foundayo Weight-Loss Pill in U.K. ↗

The once-daily pill was approved for patients with a body mass index of at least 30, or between 27 and 30 in the event…

WSJ

Aug 23 Eli Lilly launches oral weight-loss pill Foundayo in UK ↗

Eli Lilly said on Monday it has launched its oral pill, Foundayo, in the UK for weight ‌management and type 2…